> Clinicians reserve the "big gun" antibiotics for the rare cases that need them-- which reduces the cash drug companies get from pushing them through clinical

> Clinicians reserve the "big gun" antibiotics for the rare cases that need them-- which reduces the cash drug companies get from pushing them through clinical trials. This statement seems to directly contradict what the article says: "According to Sprenger, “there are no legal instruments to prohibit the use of a new antibiotic.” What that means is if a new antibiotic is released there’s no way to stop the world from overusing it. At current usage levels a new antibiotic, he says, would only have about two years on the market before bacterial resistance to it develops." If the world overuses a new antibiotic then the pharma company should be swimming in cash. And if the pharma company isn't swimming in cash because people reserve them for rare cases, then it should not be possible for the world to overuse the new antibiotic.